Skip to content
CharitiesAidWelfare, Medical Health Aged Care

$1.3 Million Partnership Between SunSense And Melanoma Institute Australia Fuels Breakthroughs In Vital Research

Ego Pharmaceuticals 2 mins read

SunSense and Melanoma Institute Australia (MIA), a global leader in melanoma research and treatment, are celebrating seven years in a partnership which has seen the Australian sunscreen brand donate more than $1.3 million towards MIA's ground-breaking research efforts. 

"MIA's mission to achieve zero deaths from melanoma by 2030 aligns perfectly with SunSense's commitment to help protect and care for the skin of all Australians," says Alan Oppenheim, Managing Director of Ego Pharmaceuticals, the makers of SunSense. "Our partnership not only supports essential research and advanced treatments but also enables us to raise awareness about sun safety and responsible sun protection habits."

MIA is at the forefront of global melanoma research and treatment, driving remarkable advancements that have led to a 50% survival rate for advanced melanoma patients. 
The partnership with SunSense enables vital funding for MIA's Personalised Immunotherapy Platform, a revolutionary approach to treating melanoma that's paving the way for better outcomes for patients.

“Long-term support from Ego Sunsense has been critical in helping fuel our ongoing research to find new and more effective treatments to save lives from melanoma,” said Melanoma Institute Australia CEO Matthew Browne. “However prevention is always better than a cure, and importantly, this partnership also amplifies our key prevention message of using sunscreen which is one of the five sun safe rules.”

As well as providing much needed financial support towards MIA’s research, the partnership is also helping to raise awareness about the dangers of UV exposure and the importance of sun safety. Melanoma, often referred to as 'Australia's national cancer,' is the most common cancer affecting 15 to 39-year-old Australians, making this education imperative.

With over 30 years of expertise, all SunSense products are made in Australia and provide broad-spectrum protection that is suitable for all skin types. As well as being fragrance-free and dermatologically tested, SunSense sunscreens are enriched with Vitamin B3 (Nicotinamide) to moisturise and visibly improve skin texture. 

This season SunSense is proudly adding two new products to its range, providing even more options for individuals and families to choose the protection that suits them best. 

SunSense Sensitive Protect SPF50 is specifically formulated for sensitive skin and children 6 months and up, and also has 4 hours water resistance, so it’s fantastic for those Summer beach days! 

SunSense Face Ultra Light SPF50+ is a lightweight facial sunscreen that’s enriched with moisturising Vitamin B3 and antioxidants, and is non-comedogenic so it won’t clog your pores. 

Available in pharmacies nationwide, SunSense remains steadfast in its dedication to helping Australians enjoy the outdoors while prioritising their skin's health.

Always read the label and follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.


Contact details:

Kim Scata
Communications & Partnerships Executive
Phone: +61 403 661 936
Email: [email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • CharitiesAidWelfare, Community
  • 17/12/2025
  • 09:21
Icon Construction & StandbyU Foundation

Community spirit on the tools: Icon supports families escaping violence

Key Facts: Icon raised over $45,000 for StandbyU Foundation through monthly BBQs and a charity auction featuring a $10,000 suit sale The funds will support families escaping domestic violence through safe accommodation initiatives and practical support Icon actively contributes to StandbyU through skills, time and resources, including helping refurbish a duplex for vulnerable families The formal handover of funds will take place at a special event on the Gold Coast on 17 December 2025 The fundraising effort demonstrates community support at a time when demand for domestic violence services is at an all-time high Community spirit on the tools: Icon…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.